Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3197109 | 1.00 | CALML3 (0.50) | CALML3GRM2MAOAMAOBCYP2C19 | |
| SCHEMBL3205152 | 0.91 | GRM2 (0.48) | CALML3GRM2S1PR5 | |
| SCHEMBL541806 | 0.88 | CALML3 (0.59) | CALML3GRM2MAOAMAOBCYP2C19 | |
| SCHEMBL541807 | 0.88 | CALML3 (0.59) | CALML3GRM2MAOAMAOBCYP2C19 | |
| SCHEMBL13486352 | 0.88 | CALML3 (0.48) | CALML3GRM2MAOAMAOBCYP2C19 | |
| SCHEMBL3198798 | 0.88 | GRM2 (0.49) | CALML3GRM2MAOBS1PR5 | |
| SCHEMBL13486203 | 0.87 | GRM2 (0.44) | CALML3GRM2S1PR5 | |
| SCHEMBL3200347 | 0.85 | CALML3 (0.52) | CALML3MAOAMAOB | |
| SCHEMBL9611100 | 0.82 | GRM2 (0.49) | CALML3GRM2S1PR5 | |
| SCHEMBL3207350 | 0.81 | FAAH (0.41) | S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-9309179-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA (FR) | 2016-04-12 | — | — | US | disclosed |
| US-9309179-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA (FR) | 2016-04-12 | — | — | US | disclosed |
| US-9309179-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA (FR) | 2016-04-12 | — | — | US | disclosed |
| US-20140213589-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA S.A.S. (FR) | 2014-07-31 | — | — | US | disclosed |
| US-20140213589-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA S.A.S. (FR) | 2014-07-31 | — | — | US | disclosed |
| US-8722746-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA S.A.S. (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722746-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA S.A.S. (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722746-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA S.A.S. (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | FAB PHARMA (FR) | 2010-02-18 | — | — | US | disclosed |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | FAB PHARMA (FR) | 2010-02-18 | — | — | US | disclosed |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | FAB PHARMA (FR) | 2010-02-18 | — | — | US | disclosed |
| EP-2010495-A2 | NEW HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | Mutabilis SA (FR) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007135562-A2 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS S.A. (FR) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007135562-A2 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS S.A. (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213589-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | HPD, HPGDS, EPX | CALML3 3469/4885GRM2 4358/4885MAOA 1013/4885 |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | HPD, HPGDS, EPX | CALML3 3469/4885GRM2 4358/4885MAOA 1013/4885 |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | HPD, HPGDS, EPX | CALML3 3469/4885GRM2 4358/4885MAOA 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.